TGNA
48
5
NKE
36
2
AMP
43
2
AON
25
4
DHI
36
3
HAL
40
11
EW
55
5
EQR
33
6
KHC
11
2
TMO
52
8
CTSH
55
3
HSIC
42
2
CRM
65
6
CTAS
36
8
HRB
40
3
DRI
74
5
MS
64
3
NRG
32
5
RF
44
10
DIS
70
2
TGNA
48
5
NKE
36
2
AMP
43
2
AON
25
4
DHI
36
3
HAL
40
11
EW
55
5
EQR
33
6
KHC
11
2
TMO
52
8
CTSH
55
3
HSIC
42
2
CRM
65
6
CTAS
36
8
HRB
40
3
DRI
74
5
MS
64
3
NRG
32
5
RF
44
10
DIS
70
2
Financhill
Back

Sarepta Therapeutics Quote, Financials, Valuation and Earnings

Elon Musk Predicts MAJOR Crisis in Trump's First Year

See Why Investors are Pouring Mountains of Cash into Certain Companies Trump Wants to Solve the Problem.
Sell
36

SRPT
Sarepta Therapeutics

Last Price:
$118.99
Seasonality Move:
12.18%

7 Day Trial

ALL ACCESS PASS

$ 7

How to Turn the AI Energy Crisis into BIG Profits

And investors who move now into one technology could make a whole lot of money.

Sarepta Therapeutics Price Quote

$118.99
+0.02 (+-0.4%)
(Updated: December 21, 2024 at 5:48 AM ET)

Sarepta Therapeutics Key Stats

Sell
36
Sarepta Therapeutics (SRPT) is a Sell
Day range:
$118.56 - $121.00
52-week range:
$91.34 - $173.25
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
7.30
P/B ratio:
9.31%
Volume:
1.7M
Avg. volume:
1.1M
1-year change:
31.76%
Market cap:
$11.4B
Revenue:
$1.2B
EPS:
$1.54

How Much Does Sarepta Therapeutics Make?

Data Unavailable

Is Sarepta Therapeutics Growing As A Company?

Data Unavailable

Sarepta Therapeutics Stock Price Performance

What Is Sarepta Therapeutics 52-Week High & Low?

Sarepta Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Sarepta Therapeutics?

Data Unavailable

Is Sarepta Therapeutics Cash Flow Positive?

Data Unavailable

Sarepta Therapeutics Return On Invested Capital

Data Unavailable

Sarepta Therapeutics Earnings Date & Stock Price

Sarepta Therapeutics Competitors

  • Who Are Sarepta Therapeutics's Competitors?
    Below is a list of companies who compete with Sarepta Therapeutics or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Arrowhead Pharmaceuticals Inc (ARWR)
    • Catalyst Pharmaceuticals Inc (CPRX)
    • Eli Lilly and Co (LLY)
    • Vertex Pharmaceuticals Inc (VRTX)

Sarepta Therapeutics Dividend Yield

Data Unavailable

Sarepta Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 66.97%
Revenue: 40.79% 15.33%

Analyst Recommendations

Buy Recommendations: 12
Hold Recommendations: 0
Sell Recommendations: 1
Price Target: 185.10
Upside from Last Price: 55.59%

Major Shareholders

Data Unavailable